Biohaven Ltd. (BHVN) |
| 11.01 0.77 (7.52%) 05-29 16:00 |
| Open: | 10.7 |
| High: | 11.995 |
| Low: | 10.55 |
| Volume: | 4,212,087 |
| Market Cap: | 1,166(M) |
| PE Ratio: | -1.98 |
| Exchange: | New York Stock Exchange |
| Industry: | Biotechnology |
| Sector: | Healthcare |
| Technical analysis | ||||
 |
||||
| sell | buy | |||
| Resistance 2: | 14.01 |
| Resistance 1: | 11.99 |
| Pivot price: | 9.48 |
| Support 1: | 9.66 |
| Support 2: | 8.22 |
| 52w High: | 18.566 |
| 52w Low: | 7.48 |
Biohaven Ltd. is a clinical-stage biopharmaceutical company. The Company focuses on development of therapies for neurological and immunoscience diseases that can change current treatment paradigms.
Financials
| EPS | -5.570 |
| Book Value | 0.860 |
| PEG Ratio | 0.00 |
| Gross Profit | 0.000 |
| Profit Margin (%) | 0.00 |
| Operating Margin (%) | 0.00 |
| Return on Assets (ttm) | -83.4 |
| Return on Equity (ttm) | -333.0 |
Company news
Sat, 30 May 2026
Analysts Offer Insights on Healthcare Companies: Biohaven Ltd. (BHVN) and Healthequity (HQY) - The Globe and Mail
Fri, 29 May 2026
Analysts Offer Insights on Healthcare Companies: Phreesia (PHR), McKesson (MCK) and Biohaven Ltd. (BHVN) - The Globe and Mail
Wed, 27 May 2026
Biohaven (BHVN) unveils epilepsy, Graves’ and IgA nephropathy data at 2026 R&D Day - Stock Titan
Wed, 27 May 2026
Biohaven - Despite Today's Gains, I Remain Skeptical (NYSE:BHVN) - Seeking Alpha
Wed, 27 May 2026
Biohaven Reports Positive Clinical Biomarker and Patient Data: First MoDE and TRAP Extracellular Protein Degraders Achieve Deep, Rapid, Selective Lowering of Disease-Driving Antibodies in Graves' Disease and IgA Nephropathy - PR Newswire
Tue, 26 May 2026
Biohaven Reports New Clinical Data in Epilepsy with Opakalim, a Selective Kv7.2/7.3 Activator, Highlighting Seizure Control and Markedly Differentiated Tolerability Profile - PR Newswire
 StockChart iOS |
 StoxlineLite iOS |
StoxlineLite iOS |
 OptionCalc iOS |
|
StockChart Android |
StoxlineLite Android |
StoxlinePro Android |
OptionCalc Android |
